GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Cashflow Statement History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Profit Before Tax | ₹868 Cr | ₹1,441 Cr | ₹1,382 Cr | ₹1,096 Cr | ₹1,301 Cr |
Adjustment | ₹1,472 Cr | ₹787 Cr | ₹645 Cr | ₹636 Cr | ₹330 Cr |
Changes In working Capital | ₹-1,074 Cr | ₹-561 Cr | ₹-386 Cr | ₹127 Cr | ₹136 Cr |
Cash Flow after changes in Working Capital | ₹1,266 Cr | ₹1,667 Cr | ₹1,641 Cr | ₹1,859 Cr | ₹1,767 Cr |
Cash Flow from Operating Activities | ₹625 Cr | ₹1,109 Cr | ₹1,131 Cr | ₹1,392 Cr | ₹1,324 Cr |
Cash Flow from Investing Activities | ₹-528 Cr | ₹-333 Cr | ₹-675 Cr | ₹-784 Cr | ₹-699 Cr |
Cash Flow from Financing Activities | ₹-77 Cr | ₹-520 Cr | ₹-442 Cr | ₹-445 Cr | ₹-739 Cr |
Net Cash Inflow / Outflow | ₹19 Cr | ₹255 Cr | ₹14 Cr | ₹164 Cr | ₹-114 Cr |
Opening Cash & Cash Equivalents | ₹1,411 Cr | ₹1,138 Cr | ₹1,110 Cr | ₹936 Cr | ₹1,233 Cr |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | ₹0.67 Cr | - | - | - | - |
Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - | - | - |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - | - |
Effect of Foreign Exchange Fluctuations | ₹12 Cr | ₹18 Cr | ₹14 Cr | ₹9.76 Cr | ₹-184 Cr |
Closing Cash & Cash Equivalent | ₹1,443 Cr | ₹1,411 Cr | ₹1,138 Cr | ₹1,110 Cr | ₹936 Cr |
Compare Cashflow Statement of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹30,464.9 Cr | 5.3% | 14.1% | 109.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 5.3% |
14.1% |
109.5% |
SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses